Literature DB >> 20937952

Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness.

Felix Geser1, John L Robinson, Joseph A Malunda, Sharon X Xie, Chris M Clark, Linda K Kwong, Paul J Moberg, Erika M Moore, Vivianna M Van Deerlin, Virginia M-Y Lee, Steven E Arnold, John Q Trojanowski.   

Abstract

BACKGROUND: Major psychiatric diseases such as schizophrenia and mood disorders have not been linked to a specific pathology, but their clinical features overlap with some aspects of the behavioral variant of frontotemporal lobar degeneration. Although the significance of pathological 43-kDa (transactivation response) DNA-binding protein (TDP-43) for frontotemporal lobar degeneration was appreciated only recently, the prevalence of TDP-43 pathology in patients with severe mental illness vs controls has not been systematically addressed.
OBJECTIVE: To examine patients with chronic psychiatric diseases, mainly schizophrenia, for evidence of neurodegenerative TDP-43 pathology in comparison with controls.
DESIGN: Prospective longitudinal clinical evaluation and retrospective medical record review, immunohistochemical identification of pathological TDP-43 in the central nervous system, and genotyping for gene alterations known to cause TDP-43 proteinopathies including the TDP-43 (TARDBP) and progranulin (GRN) genes.
SETTING: University health system. PARTICIPANTS: One hundred fifty-one subjects including 91 patients with severe mental illness (mainly schizophrenia) and 60 controls. MAIN OUTCOME MEASURES: Clinical medical record review, neuronal and glial TDP-43 pathology, and TARDP and GRN genotyping status.
RESULTS: Significant TDP-43 pathology in the amygdala/periamygdaloid region or the hippocampus/transentorhinal cortex was absent in both groups in subjects younger than 65 years but present in elderly subjects (29% [25 of 86] of the psychiatric patients and 29% [10 of 34] of control subjects). Twenty-three percent (8 of 35) of the positive cases showed significant TDP-43 pathology in extended brain scans. There were no evident differences between the 2 groups in the frequency, degree, or morphological pattern of TDP-43 pathology. The latter included (1) subpial and subependymal, (2) focal, or (3) diffuse lesions in deep brain parenchyma and (4) perivascular pathology. A new GRN variant of unknown significance (c.620T>C, p.Met207Thr) was found in 1 patient with schizophrenia with TDP-43 pathology. No known TARDBP mutations or other variants were found in any of the subjects studied herein.
CONCLUSIONS: The similar findings of TDP-43 pathology in elderly patients with severe mental illness and controls suggest common age-dependent TDP-43 changes in limbic brain areas that may signify that these regions are affected early in the course of a cerebral TDP-43 multisystem proteinopathy. Finally, our data provide an age-related baseline for the development of whole-brain pathological TDP-43 evolution schemata.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20937952      PMCID: PMC3050578          DOI: 10.1001/archneurol.2010.254

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  53 in total

Review 1.  Early features in frontotemporal dementia.

Authors:  Ana María Villamizar Caycedo; Bruce Miller; Joel Kramer; Katya Rascovsky
Journal:  Curr Alzheimer Res       Date:  2009-08       Impact factor: 3.498

2.  Where does parkinson disease pathology begin in the brain?

Authors:  Kelly Del Tredici; Udo Rüb; Rob A I De Vos; Jürgen R E Bohl; Heiko Braak
Journal:  J Neuropathol Exp Neurol       Date:  2002-05       Impact factor: 3.685

3.  The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration.

Authors:  Chang-En Yu; Thomas D Bird; Lynn M Bekris; Thomas J Montine; James B Leverenz; Ellen Steinbart; Nichole M Galloway; Howard Feldman; Randall Woltjer; Carol A Miller; Elisabeth McCarty Wood; Murray Grossman; Leo McCluskey; Christopher M Clark; Manuela Neumann; Adrian Danek; Douglas R Galasko; Steven E Arnold; Alice Chen-Plotkin; Anna Karydas; Bruce L Miller; John Q Trojanowski; Virginia M-Y Lee; Gerard D Schellenberg; Vivianna M Van Deerlin
Journal:  Arch Neurol       Date:  2010-02

4.  Elderly patients with schizophrenia exhibit infrequent neurodegenerative lesions.

Authors:  S E Arnold; B R Franz; J Q Trojanowski
Journal:  Neurobiol Aging       Date:  1994 May-Jun       Impact factor: 4.673

5.  Human non-synonymous SNPs: server and survey.

Authors:  Vasily Ramensky; Peer Bork; Shamil Sunyaev
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

Review 6.  Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases.

Authors:  Felix Geser; Maria Martinez-Lage; Linda K Kwong; Virginia M-Y Lee; John Q Trojanowski
Journal:  J Neurol       Date:  2009-03-07       Impact factor: 4.849

Review 7.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

8.  Transactivation response DNA-binding protein 43 microvasculopathy in frontotemporal degeneration and familial Lewy body disease.

Authors:  Wen-Lang Lin; Monica Castanedes-Casey; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2009-11       Impact factor: 3.685

9.  Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia.

Authors:  Konrad Talbot; Wess L Eidem; Caroline L Tinsley; Matthew A Benson; Edward W Thompson; Rachel J Smith; Chang-Gyu Hahn; Steven J Siegel; John Q Trojanowski; Raquel E Gur; Derek J Blake; Steven E Arnold
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

10.  A new subtype of frontotemporal lobar degeneration with FUS pathology.

Authors:  Manuela Neumann; Rosa Rademakers; Sigrun Roeber; Matt Baker; Hans A Kretzschmar; Ian R A Mackenzie
Journal:  Brain       Date:  2009-08-11       Impact factor: 13.501

View more
  53 in total

1.  Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old.

Authors:  John L Robinson; Felix Geser; Maria M Corrada; Daniel J Berlau; Steven E Arnold; Virginia M-Y Lee; Claudia H Kawas; John Q Trojanowski
Journal:  Brain       Date:  2011-11-26       Impact factor: 13.501

Review 2.  Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants.

Authors:  Shahram Saberi; Jennifer E Stauffer; Derek J Schulte; John Ravits
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

3.  Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy.

Authors:  Felix Geser; Beth Stein; Michael Partain; Lauren B Elman; Leo F McCluskey; Sharon X Xie; Vivianna M Van Deerlin; Linda K Kwong; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2011-01-12       Impact factor: 17.088

Review 4.  On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia.

Authors:  F Geser; D Prvulovic; L O'Dwyer; O Hardiman; P Bede; A L W Bokde; J Q Trojanowski; H Hampel
Journal:  Prog Neurobiol       Date:  2011-09-03       Impact factor: 11.685

5.  Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype.

Authors:  Shunsuke Koga; Naomi Kouri; Ronald L Walton; Mark T W Ebbert; Keith A Josephs; Irene Litvan; Neill Graff-Radford; J Eric Ahlskog; Ryan J Uitti; Jay A van Gerpen; Bradley F Boeve; Adam Parks; Owen A Ross; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2018-06-20       Impact factor: 17.088

6.  Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains.

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; Amanda M Serie; Ralph B Perkerson; Billie J Matchett; Clifford R Jack; David S Knopman; Ronald C Petersen; Joseph E Parisi; Leonard Petrucelli; Matthew Baker; Rosa Rademakers; Jennifer L Whitwell; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2019-01-02       Impact factor: 17.088

7.  TAR DNA-binding protein 43 pathology in Alzheimer's disease with psychosis.

Authors:  Anil Varma V Vatsavayi; Julia Kofler; Mary Ann A Demichele-Sweet; Patrick S Murray; Oscar L Lopez; Robert A Sweet
Journal:  Int Psychogeriatr       Date:  2014-03-04       Impact factor: 3.878

8.  TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.

Authors:  Bryan D James; Robert S Wilson; Patricia A Boyle; John Q Trojanowski; David A Bennett; Julie A Schneider
Journal:  Brain       Date:  2016-11-01       Impact factor: 13.501

9.  A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology.

Authors:  Takenari Yamashita; Takuto Hideyama; Kosuke Hachiga; Sayaka Teramoto; Jiro Takano; Nobuhisa Iwata; Takaomi C Saido; Shin Kwak
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

10.  Parkin ubiquitinates Tar-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6).

Authors:  Michaeline L Hebron; Irina Lonskaya; Kaydee Sharpe; Puwakdandawe P K Weerasinghe; Norah K Algarzae; Ashot R Shekoyan; Charbel E-H Moussa
Journal:  J Biol Chem       Date:  2012-12-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.